Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2022 Earnings Conference Call March 2, 2023 5:00 PM ET Company Participants Carrie Siragusa – Executive Director, Corporate Strategy and Investor Relations Lonnel Coats – Chief Executive Officer Jeff Wade – President and Chief Financial Officer Craig Granowitz – Senior Vice President and Chief Medical Officer Conference Call Participants Yasmeen Rahimi – Piper Sandler Carly Kenselaar – Citi Joseph Stringer – Needham & Company Operator Good afternoon, and welcom ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 000-30111 Lexicon Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 76-0 ...

Financial Data and Key Metrics Changes - The company ended Q3 2022 with $136.2 million in cash and investments, including net proceeds of $94.3 million from a public offering and private placement [29] - Research and development expenses decreased to $10.6 million from $15.7 million in Q3 2021, primarily due to lower external clinical research expenses [32] - Selling, general and administrative expenses increased to $12.6 million from $7.3 million in Q3 2021, mainly due to increased personnel and external expenses related to the commercial launch preparations [33] - The net loss for Q3 2022 was $23.4 million, or $0.13 per share, compared to a net loss of $23.1 million, or $0.16 per share, in Q3 2021 [33] Business Line Data and Key Metrics Changes - The company is actively developing two lead programs: sotagliflozin for heart failure and LX9211 for neuropathic pain [8] - Sotagliflozin is positioned to enter the heart failure market, with a PDUFA target action date anticipated in May 2023 [9] - LX9211 has shown positive top-line results in a Phase II proof-of-concept study for painful diabetic neuropathy, with final data to be presented at an upcoming summit [10][27] Market Data and Key Metrics Changes - Over 6 million people in the U.S. are living with heart failure, with about 1 million new cases diagnosed each year, indicating a large and growing market [11] - Heart failure is the leading cause of hospitalization for Americans over 65, with approximately 1 million hospitalizations annually [12] Company Strategy and Development Direction - The company aims to differentiate sotagliflozin in the heart failure market through unique data from the SOLOIST-WHF trial, which demonstrated significant effects on reducing cardiovascular mortality and hospital readmissions [9][18] - The company is exploring potential partnerships for LX9211 to advance its development and is engaged in discussions to find a strategic fit [26][61] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming regulatory review for sotagliflozin, noting no significant issues were raised during the mid-cycle review meeting with the FDA [8][37] - The company anticipates launching sotagliflozin in the U.S. in the first half of 2023, contingent on regulatory approval [66] Other Important Information - The company has been granted fast track designation by the FDA for LX9211 in diabetic peripheral neuropathic pain [20] - The final results of the RELIEF-DPN trial will be presented at the 16th Annual Pain Therapeutic Summit, providing further insights into the efficacy of LX9211 [27] Q&A Session Summary Question: Did the FDA request additional data during the mid-cycle review? - Management confirmed that the FDA did not request any new data, indicating a comprehensive submission package [37] Question: Can you elaborate on the potential unique label for sotagliflozin? - Management indicated confidence in obtaining label elements for recent worsening heart failure, as this was the population studied in the SOLOIST trial [39] Question: What differentiates sotagliflozin from other SGLT2 inhibitors? - Management highlighted that other SGLT2 data did not show significant separation until 90 days, while sotagliflozin demonstrated a 52% reduction in all-cause death or heart failure-related events at 90 days [50] Question: What are the plans for LX9211 beyond diabetic neuropathy? - Management noted that preclinical data supports exploring other types of neuropathic pain and potential applications in spasticity [61]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 000-30111 Lexicon Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) (Sta ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorporation or Organization) (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission ...

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q2 2022 Earnings Conference Call August 2, 2022 5:00 PM ET Company Participants Mike Kelly - Investor Relations Lonnel Coats - Chief Executive Officer Jeff Wade - President & Chief Financial Officer Craig Granowitz - Senior Vice President & Chief Medical Officer Conference Call Participants Yigal Nochomovitz - Citigroup Joseph Stringer - Needham & Company Operator Good afternoon, ladies and gentlemen and welcome to the Lexicon Pharmaceuticals Inc. Second Quarter 2 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 000-30111 Lexicon Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) (State o ...

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2022 Results Conference Call May 5, 2022 8:00 AM ET Company Participants Charles Schultz - Investor Relations Lonnel Coats - President and Chief Executive Officer Jeffrey Wade - President and Chief Financial Officer Craig Granowitz - Senior Vice President and Chief Medical Officer Conference Call Participants Jessica Fye - JP Morgan Joseph Stringer - Needham & Company Operator Good morning. This is Jesse, and I will be your conference operator today. At this ti ...

(Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 or UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 000-30111 Lexicon Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) (State or Oth ...

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2021 Earnings Conference Call February 28, 2022 8:00 AM ET Company Participants Chas Schultz - Executive Director, Corporate Communications and Investor Relations Lonnel Coats - Chief Executive Officer Jeff Wade - President and Chief Financial Officer Craig Granowitz - Senior Vice President and Chief Medical Officer Conference Call Participants Joseph Stringer - Needham Julian Harrison - BTIG Disclaimer*: This transcript is designed to be used alongside the fre ...